Early HIV treatment may shield immune cells from lasting damage
NCT ID NCT02656511
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests whether starting antiretroviral therapy right away during the first weeks of HIV infection can protect key immune cells from being destroyed. Adults with very early HIV (infected within the last 90 days) receive a combination of dolutegravir and emtricitabine/tenofovir. Researchers will measure safety, side effects, and changes in the amount of hidden HIV in the blood and tissues over six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of dolutegravir and emtricitabine/tenofovir
- What this could lead to
- If successful, this approach could help preserve immune function and reduce the amount of hidden HIV in the body, potentially leading to better long-term outcomes for people diagnosed early.
- What could go wrong
- This is a small, early-phase study without a comparison group, so results may not apply to everyone. The treatment may cause side effects, and it is not known if early treatment alone can eliminate the virus.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
San Francisco General Hospital
San Francisco, California, 94110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Small cash rewards may keep HIV-positive mothers in treatment — a trial puts the idea to the test
- Choice may boost HIV prevention: a trial tests offering multiple PrEP options to young women in kenya
- Home care plus nutrition may cut post-hospital deaths in HIV — a trial puts it to the test
- Heavy drinking and risky sex: a text-based intervention aims to cut HIV risk
- Pharmacists on the front line: a new strategy to fight heart disease in people with HIV
- Fighting HIV stigma: a cultural approach to keep patients in care